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Abstract
Background: A variant in the promoter of the human uncoupling protein 2 (UCP2) gene, the G-866A polymorphism, has been
associated with future risk of coronary heart disease events, in those devoid of traditional risk factors and in those suffering
from diabetes. We thus examined the impact of the G-866A polymorphism on 5-year survival in a cohort of 901 post-myocardial
infarction patients, and the impact of type-2 diabetes on this relationship. The association of UCP2 with baseline biochemical and
hormonal measurements, including levels of the inflammatory marker myeloperoxidase, was also examined.
Methods:  UCP2 G-866A genotypes were determined using a polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) protocol. Myeloperoxidase levels were measured in plasma samples taken from 419 cohort patients
24–96 hours after admission.
Results: Genotypes were obtained for 901 patients with genotype frequencies AA 15.5%, GA 45.5%, and GG 39.0%. Genotype
was not associated with survival in the overall cohort (mortality: AA 15.6%, GA 16.8%, GG 19.4%, p = 0.541). However, amongst
diabetics, AA and GA genotype groups had significantly worse survival than GG diabetic patients (p < 0.05) with an attributable
risk of 23.3% and 18.7% for those of AA and GA genotype respectively. Multivariate analysis using a Cox proportional hazards
model confirmed that the interaction of diabetes with genotype was significantly predictive of survival (p = 0.031). In the cohort's
diabetic subgroup AA/GA patients had higher myeloperoxidase levels than their GG counterparts (GA/AA, n = 51, 63.9 ± 5.23;
GG, n = 34, 49.1 ± 3.72 ng/ml, p = 0.041). Further analysis showed that this phenomenon was confined to male patients (GA/
AA, n = 36, 64.3 ± 6.23; GG, n = 29, 44.9 ± 3.72 ng/ml, p = 0.015).
Conclusion: Diabetic patients in this post-myocardial infarction cohort with UCP2 -866 AA/GA genotype have poorer survival
and higher myeloperoxidase levels than their GG counterparts.
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Background
Uncoupling protein 2 (UCP2) is expressed ubiquitously
and is believed to dissipate the proton motive force across
the inner mitochondrial membrane [1,2]. While UCP1
may play a role in thermogenesis [3], UCP2 may regulate
inflammation and apoptosis, and inhibition of the mito-
chondrial production of reactive oxygen species (ROS)
[4]. These functions have important implications for
brain and heart disease. experimental inhibition of UCP2
expression increases ROS formation [5,6], a risk factor for
atherosclerosis [7]. UCP2 has recently been shown to
mediate some of the actions of ghrelin [8], a circulating
hormone elevated during fasting and with known actions
on the heart [9].
Polymorphisms in the UCP2 gene have been associated
with obesity [10-12], hypertension [13], and diabetes
[14]. A common variant in the promoter of the human
UCP2 gene (G-866A, rs659366)[11] has been associated
with differential UCP2 expression [12] and elevated levels
of markers of oxidative stress amongst diabetics [15,16].
The A allele has been associated with enhanced UCP2
expression in adipose tissue in vivo[11]. Indeed, in a pro-
spective study of 2695 men, those with -866AA genotype
exhibited a greater prevalence of obesity and hyperten-
sion, and a shorter time to first coronary heart disease
(CHD) event. This risk was amplified fourfold in diabetic
-866AA men [15].
The enzyme myeloperoxidase (MPO, EC 1.11.1.7) is
mainly released by activated neutrophils with pro-oxida-
tive and pro-inflammatory properties. Given the role of
inflammation in atherogenesis, MPO is a biomarker of
coronary artery disease [17]. Meanwhile, infiltrating mac-
rophages and neutrophils play a role in the destabiliza-
tion of coronary artery plaques and thus in the
pathogenesis of acute coronary syndromes including
myocardial infarction (MI)[18].
We thus hypothesized that the UCP2 G-866A polymor-
phism might be associated with survival in a study sample
at high risk of future cardiovascular events, and that this
relationship might be stronger amongst diabetics. Given
the proinflammatory role of UCP2 [4], we also sought
association of UCP2 genotype with plasma MPO levels in
this group.
Methods
Study Population
Patients were admitted to Christchurch Hospital between
November 1994 and June 2001 and recruited to the
Christchurch Post-Myocardial Infarction (PMI) study
using criteria described previously [19]. Briefly, MI was
defined by typical ischemic symptoms, ischemic change
(including ST-elevation or depression or dynamic T-wave
changes, i.e. includes ST-elevation, non-ST-elevation, Q-
wave, and non-Q-wave infarcts) in two or more electro-
cardiogram leads and peak elevation of plasma creatine
kinase (CK) to at least twice the upper limit of normal. All
patients were troponin-T positive. Inclusion criteria
included age <80 years, absence of immediate heart fail-
ure or cardiogenic shock, and survival for at least 24 h
after the onset of symptoms associated with MI. Patients
were followed for 5 years and data on mortality/survival
for the full 5 years of follow-up was available for all
patients in the cohort. Blood samples and cardiac imaging
were obtained 24–96 h after symptom onset. Clinical
events were determined from recruitment questionnaires,
planned follow-up clinic visits, patient notes, the New
Zealand National Health Information Service and hospi-
tal Patient Management System databases. Ethnicity was
self-declared and was grouped as those of European,
Maori, Not Stated and Other (Asian, African and Pacific
Islanders) ancestry. The investigation conforms to the
principles outlined in the Declaration of Helsinki and was
approved by the Canterbury Ethics Committee. All partic-
ipating patients provided written, informed consent.
Dna Extraction and Genotyping
Genomic DNA was extracted from whole blood as previ-
ously described [20]. DNA (100 ng) was amplified for the
UCP2 G-866A PCR-RFLP assay, in which 360 bp amplim-
ers were digested for 16 h at 37°C using 2.5 U of MluI
[11]. The digested, gel-electrophoresed fragments were
visualized using a Bio-Rad Fluor-S™ imaging system.
Neurohormone, Analyte and Cardiac Imaging 
Measurements
Circulating levels of endothelin-1, ANP and B-type natri-
uretic peptide (BNP) and N-terminal pro-BNP
(NTproBNP) were assayed as previously described [19].
creatinine clearance was calculated using the Cockcroft-
Gault formula [21]. Levels of creatine kinase (CK) were
measured using ELISA kits (Roche Diagnostics, Auckland,
NZ). Left ventricular function was assessed by radionu-
clide ventriculography – within 24–96 hours of onset of
MI (within 24 hours of blood sampling) [22]. Myeloper-
oxidase (EC 1.11.1.7) was measured by sandwich ELISA
on plasma diluted 1:10, with a monoclonal antibody
(Abcam, Cambridge, United Kingdom) and a rabbit poly-
clonal antibody produced in-house [23], with a detection
range of 0.3 to 25 ng/ml and coefficient of variance of
13.8%.
Statistical Analysis
Univariate analysis, relating UCP2 G-866A genotype sta-
tus to other variables, was performed using χ2  and
ANOVA tests. Skewed data (notably plasma hormones)
were log-transformed. Survival was assessed using Kaplan-
Meier survival curves and log-rank tests. Due to the smallCardiovascular Diabetology 2009, 8:31 http://www.cardiab.com/content/8/1/31
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number of UCP2 -866 AA patients for which MPO levels
were available data for AA and GA patients was grouped
for this analysis. A Cox proportional hazard model was
used to investigate independent risk factors for all-cause
mortality. The model included established predictors of
prognosis (age, gender, NTproBNP and CK levels, admis-
sion left ventricular ejection fraction (LVEF), β-blocker
treatment, and creatinine clearance) [20,22,24,25]. Statis-
tical significance was deemed to be achieved at the p <
0.05 level. The statistical power of the study was estimated
from the cohort's likely genotype split of ~15% (AA) and
~42.5% (GG or GA respectively)[11,15] with a total n of
~900 and an event (mortality) rate of approximately 3%
per annum and complete follow-up to 5 years. Thus there
was 80% power to detect >10% difference in mortality
between the two homozygote groups, using a two-tailed
χ2 test, α = 0.05. All analyses were performed using SPSS
version 16.
Results
Baseline Characteristics and UCP2 Genotyping
Of an available cohort of 982, genotypes were obtained
for 901 patients with genotype frequencies AA 15.5%, GA
45.5%, and GG 39.0% which did not deviate from the
Hardy-Weinberg equilibrium (p = 0.999). The minor
allele (A) frequency was 0.38, similar to that reported else-
where [11,15]. Baseline characteristics stratified by UCP2
G-866A genotype group are shown in Table 1, and did not
differ from those in whom genotyping was not possible.
Only patient gender was significantly associated with gen-
otype, with the proportion of males increasing with the
number of G alleles. Ethnicity was not significantly asso-
ciated with differences in genotype frequency (minor
allele frequencies: European 0.375, Maori 0.438, Not
Stated 0.442, Other 0.371, p = 0.481).
Survival and UCP2 Genotype
A total of 159 deaths were recorded in the study cohort
during the 5-year follow-up. UCP2 G-866A genotype was
Table 1: Baseline characteristics, drug treatment and neurohormonal data stratified by UCP2 genotype group.
UCP2 Genotype
nA AnG AnG G p
Gender (M/F) 140 102/38(72.9%M) 410 309/101(75.4%M) 351 292/59 (83.2%M) 0.009
Age (years)* 140 61.5 ± 0.94 410 62.0 ± 0.49 350 62.7 ± 057 0.404
BMI* (kgm-2) 92 27.2 ± 0.51 285 26.9 ± 0.25 239 26.4 ± 0.25 0.174
LVEF 113 47.2 ± 1.00 348 48.0 ± 0.64 288 47.9 ± 0.72 0.822
Predischarge Mean arterial pressure (mmHg) 133 82.9 ± 0.87 397 83.2 ± 0.55 341 84.6 ± 0.61 0.145
Predischarge Systolic Blood pressure (mmHg) 133 117 ± 1.28 397 116 ± 0.81 341 118 ± 0.90 0.163
Predischarge Diastolic Blood pressure (mmHg)(mmHg) 133 65.9 ± 0.82 397 66.8 ± 0.54 341 67.8 ± 0.57 0.176
History
Previous myocardial infarction* 127 24(18.9%) 389 72 (18.5%) 334 58 (17.4%) 0.896
hypertension * 129 47(36.4%) 400 157 (39.3%) 342 131 (38.3%) 0.847
Type 2 Diabetes* 139 22(15.8%) 409 48(11.7%) 349 38 (10.9%) 0.308
Predischarge Atrial Fibrillation*
Fibrillation*
112 12(10.7%) 346 35 (10.1%) 297 47 (15.8%) 0.076
Predischarge Ventricular Fibrillation* Fibrillation* 113 11(9.7%) 355 40 11.3%) 300 21 (7.0%) 0.173
Laboratory Data
Total Cholesterol* (mmol/l) 130 5.94 ± 0.10 376 5.95 ± 0.065 330 5.81 ± 0.068 0.325
HDL Cholesterol* (mmol/l) 129 1.16 ± 0.026 371 1.16 ± 0.017 325 1.15 ± 0.018 0.913
LDL Cholesterol* (mmol/l) 97 3.96 ± 0.10 299 3.98 ± 0.058 268 3.83 ± 0.069 0.225
Triglycerides* (mmol/l) 130 2.02 ± 0.11 376 2.08 ± 0.096 330 2.01 ± 0.069 0.791
Plasma Creatinine† (μmol/l) 136 83 (79–87) 405 85 (82–87) 347 85 (83–87) 0.600
Creatinine Clearance* (ml/s) 99 1.28 ± 0.047 308 1.28 ± 0.023 267 1.32 ± 0.028 0.546
Peak Creatine kinase† (units/l) 105 1440(1250–1660) 327 1610(1480–1740) 269 1640(1510–1680) 0.304
Plasma Glucose (mmol/l) 137 8.55 ± 0.27 404 8.64 ± 0.15 344 8.55 ± 0.16 0.912
Glycated Hemoglobin % 105 6.07 ± 0.11 324 6.06 ± 0.06 274 6.03 ± 0.06 0.905
Discharge Medications
ACE inhibitor * 122 36(29.5%) 374 121 (32.4%) 318 109 (34.3%) 0.624
β-blocker * 122 78(63.9%) 374 232 (62.0%) 318 176 (55.3%) 0.119
Neurohormonal Data
ANP (pmol/l)‡ 138 26.8(24.4–29.4) 403 28.5(27.0–30.0) 346 28.8(27.1–30.6) 0.406
BNP (pmol/l)‡ 138 18.2(16.4–20.2) 404 19.8(18.7–21.0) 346 19.9(18.8–21.1) 0.290
NTproBNP (pmol/l)‡ 137 98.6(87.0–112) 399 112(104–121) 344 111(103–121) 0.200
Endothelin-1 (pmol/l)‡ 137 1.64(1.52–1.77) 398 1.80(1.73–1.88) 340 1.76(1.167–1.81) 0.110
*Means (SEM) or occurrence (percentage); †Median (range); ‡Geometric mean (95% confidence interval).Cardiovascular Diabetology 2009, 8:31 http://www.cardiab.com/content/8/1/31
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A Kaplan-Meier survival curve indicating differences in survival after MI for UCP2 G-866A genotype groups in A) non-diabetic  patients and B) diabetic patients Figure 1
A Kaplan-Meier survival curve indicating differences in survival after MI for UCP2 G-866A genotype groups in 
A) non-diabetic patients and B) diabetic patients.Cardiovascular Diabetology 2009, 8:31 http://www.cardiab.com/content/8/1/31
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not associated with survival in the overall cohort (mortal-
ity: AA 15.6%, GA 16.8%, GG 19.4%, p = 0.541). How-
ever when the cohort was stratified according to prior
diagnosis of type-2 diabetes, genotype was significantly
associated with survival amongst diabetic patients (Figure
1). Diabetic patients of AA or GA genotype had signifi-
cantly worse survival than GG diabetic patients (p < 0.05),
with an attributable risk of 23.3% and 18.7% respectively.
Multivariate analysis using a Cox proportional hazards
model confirmed that UCP2 G-866A genotype alone was
not a significant predictor of survival in the cohort,
although there were trends in that direction (Table 2).
However the interaction of diabetes with genotype was
significantly predictive of survival in a model including
age, gender, NTproBNP and CK levels, left ventricular
ejection fraction, creatinine clearance, ethnicity, β-blocker
treatment, diabetes and genotype (Table 2). Inclusion of
additional covariates to the multivariate model did not
add significantly to it (e.g. baseline total cholesterol Haz-
ard Ratio = 1.17 [0.96–1.43] p = 0.131; mean arterial pres-
sure HR = 1.01 [0.99–1.04] p = 0.240) and exceeded the
recommended number of predictors given the number of
events in the analysis.
UCP2 Genotype and Plasma Myeloperoxidase Levels
Plasma MPO levels were available from samples taken
from 419 patients in the cohort 24–96 hours after admis-
sion. These patients were selected only by the availability
of adequate stored plasma for the measurement of MPO
and we believe this selection was essentially random.
Whilst there was no overall association of UCP2 genotype,
diabetic status or gender with MPO levels, there was a sig-
nificant interaction of gender*diabetic status*UCP2 gen-
otype in a univariate general linear model (p = 0.037). In
the diabetic subgroup of the cohort, patients with at least
one A allele had significantly higher MPO levels than their
GG counterparts (GA/AA, n = 51, 63.9 ± 5.23 ng/ml; GG,
n = 34, 49.1 ± 3.72 ng/ml, p = 0.041; Figure 2). This phe-
nomenon was only apparent in male patients (GA/AA, n
= 36, 64.3 ± 6.23 ng/ml; GG, n = 29, 44.9 ± 3.72 ng/ml, p
= 0.015; Figure 2). There was no significant association
between genotype and MPO levels in female diabetic
patients (GA/AA, n = 15, 62.9 ± 9.99 ng/ml; GG, n = 5,
73.5 ± 6.17 ng/ml, p = 0.561) or amongst non-diabetic
patients (data not shown). MPO levels did not differ sig-
nificantly between diabetic and non-diabetic patients
(diabetics, n = 85, 58.0 ± 3.27 ng/ml; non-diabetics, n =
334, 63.7 ± 2.21 ng/ml, p = 0.223).
Discussion
The major finding of this study is that the interaction
between type-2 diabetes and UCP2 G-866A genotype was
significantly associated with survival in a cohort of post-
MI patients. The UCP2-866A allele carriers had signifi-
cantly worse survival during 5 years of follow-up post-MI
than GG patients if they were diabetic. These data extend
previous observations amongst otherwise healthy men in
whom the UCP2 G-866A genotype was associated with
future risk of CHD events, both in those individuals
devoid of traditional risk factors for cardiovascular disease
and amongst the small proportion of diabetic patients
[15]. In contrast a study of 3122 type-2 diabetic patients
reported association of the UCP2  -866 A allele with
decreased risk of incident coronary artery disease, includ-
ing sudden cardiac death [26]. The disease-free survival
profile in this report closely resembles the survival curve
for non-diabetic patients in our study (Figure 1A). This
inconsistency may have several explanations: study end-
points differed (survival versus disease-free survival) and
differing age and ethnic profiles.
Table 2: Cox's proportional hazards regression model for mortality in the PMI cohort.
Coefficient SE Wald df Significance Hazard Ratio 95% CI for Hazard Ratio
Age 0.018 0.016 1.40 1 0.237 1.02 0.99–1.05
Gender 0.587 0.270 4.71 1 0.030 1.80 1.06–3.06
ACE inhibitor (No/Yes) 0.235 0.229 1.06 1 0.303 1.27 0.81–1.98
LVEF (1–4 days post-MI) -0.013 0.011 1.48 1 0.224 0.99 0.97–1.01
Log10 NTproBNP* 1.55 0.409 14.3 1 <0.001 4.70 2.11–10.5
Log10 peak creatine kinase* 1.11 0.338 10.8 1 0.001 3.04 1.56–5.88
Creatinine clearance -0.900 0.384 5.49 1 0.019 0.406 0.19–0.86
Ethnicity (European v non-European) 1.05 0.597 3.11 1 0.078 2.86 0.89–9.21
Type 2 Diabetes 0.847 0.602 1.98 1 0.159 2.33 0.72–7.59
UCP2 G-866A genotype 4.91 2 0.086
GG v AA 1.64 0.747 4.79 1 0.029 5.13 1.19–22.2
GG v GA 1.16 0.684 2.89 1 0.089 3.19 0.841–12.2
Diabetes × UCP2 genotype 6.92 2 0.031
Diabetes × UCP2 genotype(GG v AA) 1.52 0.725 4.40 1 0.036 4.59 1.10–18.9
Diabetes × UCP2 genotype(GG v GA) 2.09 0.826 6.40 1 0.011 8.06 1.60–40.0
* Hazard Ratio represents the change in risk for every 10-fold increase in measurement level.Cardiovascular Diabetology 2009, 8:31 http://www.cardiab.com/content/8/1/31
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Plasma myeloperoxidase levels 24–96 hours after index patient admission stratified by UCP2 G-866A genotype and diabetic  status a) Male and Female patients, b) Male patients Figure 2
Plasma myeloperoxidase levels 24–96 hours after index patient admission stratified by UCP2 G-866A geno-
type and diabetic status a) Male and Female patients, b) Male patients. N = non-diabetic, Y = diabetic. Stars and cir-
cles indicate outlying data.
 
 
 
 
 
 
 
 
B) Males only 
A) Males and Females 
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Diabetes is associated with increased oxidative stress [27]
and diabetic patients with the UCP2-866AA genotype and
CHD have been shown to have lower total antioxidant
status and higher levels of plasma F2-isoprostanes [15].
Elevated levels of plasma MPO, has previously been
shown to be a predictor of mortality in the cohort studied
in this report [28]. The difference observed in MPO levels
between GA/AA and GG diabetic patients was of similar
magnitude to that observed between heart healthy control
subjects and PMI patients in the previous report [28]. We
did not include MPO as a predictor in the multivariate
model of survival as missing data would have severely
restricted the number of patients in the analysis. While
this data was not well powered to detect differences in
MPO levels based on UCP2 genotypes groups, we did
detect an association of MPO levels and genotype
amongst diabetic patients in this study. This was particu-
larly evident in male diabetic patients in the cohort, a
finding consistent with previous reports of gender specific
differences in oxidative stress [29,30]. This finding of an
association between UCP2 G-866A genotype and plasma
MPO levels can be regarded as hypothesis generating and
requires validation in other studies.
Although the current study has considerable statistical
power, due to the size of the cohort, the length of follow-
up, the number of clinical endpoints recorded and the
minor allele frequency of the G-866A polymorphism, sta-
tistically significant differences may have occurred by
chance and weak associations may have been missed.
Missing data for some parameters has limited the power
of this study to investigate their association with geno-
type. The study cohort was dominated by ethnic Europe-
ans and the results should not be extrapolated to other
populations.
Conclusion
Our data provide support for the idea that modulation of
UCP2 expression might be an important novel target for
reducing cardiovascular morbidity and mortality, particu-
larly amongst diabetic patients [31]. A growing body of
evidence supports the UCP2 G-866A polymorphism as a
marker of cardiovascular risk [15,16,32]. This study
extends this evidence to include UCP2 genotype as a
potential marker of prognosis in type-2 diabetes patients
following acute MI.
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